Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Mont-Saint-Guibert, Belgium – 9 th February 2021 – Nyxoah SA ...

The Genio system is now available in the US for OSA patients who meet eligibility criteria. The Food and Drug Administration (FDA) has approved the Genio ® system for the treatment of patients with ...

Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for ...

(RTTNews) - Nyxoah SA (NYXH), a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), announced the successful implantation of its Genio system in the ...

(RTTNews) - Nyxoah S.A. (NYXH) has announced the commercial launch of its Genio system in the Middle East, with the first successful implant performed at Saudi German Hospital in Dubai, UAE. Genio is ...

Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough ...

Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for ...

Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1 ...